You are here: Home » Markets ¬Ľ News
Share of direct plans in SIPs rises to 31% in three years, shows data
icon-arrow-left
Business Standard

Prescription for recovery in FY23 for underperforming pharma sector

Easing pricing pressures, complex generics uptick in the US, steady India/emerging-market growth potential booster shots

Topics
Nifty Pharma | Pharma sector | US markets

Ram Prasad Sahu  |  Mumbai 



Pharmacy
Photo: Shutterstock

The Index was the second-worst performer among Nifty sectoral indices over the past year, shedding over 13 per cent in trade. Over a two-year period, its underperformance has grown starker. It is the only index to generate a mid single-digit return (6 per cent), with its closest competitor enriching investors by over 35 per cent.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Mon, September 26 2022. 06:10 IST

RECOMMENDED FOR YOU

.